CODEXIS, INC.

REDWOOD CITY, CA · Biotech · Public

Custom engineered enzymes and biocatalysts for RNA and pharmaceutical manufacturing

Claim this profile

Follows are private to you and power your alerts

Updated · codexis.com

Sector
Biotech
Headquarters
REDWOOD CITY, CA
Latest Form D
$50M, Jun 2019
Total capital
$50M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$50M
1 Form D · last Jun 2019
88 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
18
22 pending · first 2025
Rank in peer group#3 of 1449

Capital timeline

2019FEDERAL ↑EQUITY ↓Cumulative $50M1st Form D$50M
2019FEDERAL ↑EQUITY ↓Cumulative $50M1st Form D$50M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$50M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#3 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Bernard KelleyDirectorNamed in SEC Form D filings
  • Byron DorganDirectorNamed in SEC Form D filings
  • David SmithDirectorNamed in SEC Form D filings
  • Dennis WolfDirectorNamed in SEC Form D filings
  • Gordon SangsterExecutive OfficerNamed in SEC Form D filings
  • John NicolsExecutive Officer, DirectorNamed in SEC Form D filings
Show all 10 people
  • Kathleen GlaubDirectorNamed in SEC Form D filings
  • Pam ChengDirectorNamed in SEC Form D filings
  • Patrick YangDirectorNamed in SEC Form D filings
  • Thomas BaruchDirectorNamed in SEC Form D filings

What it has protected

USPTO · 18 granted of 40
  • GrantedEngineered Dna Ligase VariantsUSPTOUS 12,729,376
  • PendingEngineered Terminal Deoxynucleotidyl Transferase VariantsUSPTOApplication 19442440
  • PendingEngineered Ligase VariantsUSPTOApplication 19202288
Show all 40 patent records
  • IN8BIO, INC.Similar federal contract value in Biotech · null in contracts
  • Convergent TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Amylyx Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
  • SurrozenSimilar federal contract value in Biotech · null in contracts
  • Clene Nanomedicine, Inc.Similar federal contract value in Biotech · null in contracts
  • TNA Therapeutics Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .